Top Markets
Coin of the day
AIM ImmunoTech Inc. AIM ImmunoTech Inc.

AIM ImmunoTech Inc.

AIM
Rang in Aktien #38741
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida,... AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Aktienkurs
$0.2438
Marktkapitalisierung
$829.78K
Veränderung (1 Tag)
-5.61%
Veränderung (1 Jahr)
-89.93%
Land
US
Handel AIM ImmunoTech Inc. (AIM)

Kategorie

Aktien-Split-Historie für AIM ImmunoTech Inc. (AIM)
Die Aktie AIM ImmunoTech Inc. (Symbol: AIM) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 14, 2026 statt.
Eine AIM-Aktie, die vor dem Aug 14, 2026 gekauft wurde, entspricht heute 0 AIM-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE